We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+56.31%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$15.6M
Cap. Flow
+$1.11M
Cap. Flow %
0.95%
Top 10 Hldgs %
40.03%
Holding
80
New
28
Increased
7
Reduced
10
Closed
27

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$3.86M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$2.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$2.35M
4
MOR
MorphoSys AG American Depositary Shares
MOR
+$2.29M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$2.17M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$5.54M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$2.78M
3
GPCR icon
Structure Therapeutics
GPCR
+$2.78M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$2.75M
5
LEGN icon
Legend Biotech
LEGN
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 98.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.07T
$7.55M 6.46%
9,700
– –
RDY icon
2
Dr. Reddy's Laboratories
RDY
$9.84B
$6.31M 5.4%
430,000
-20,000
-4% -$292K
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$5.76M 4.93%
36,800
+24,000
+188% +$3.86M
CI icon
4
Cigna
CI
$76.2B
$5.56M 4.76%
15,300
– –
ALPN
5
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.64M 3.97%
117,000
-56,500
-33% -$1.67M
TGTX icon
6
TG Therapeutics
TGTX
$8.34B
$3.5M 3%
230,300
+27,000
+13% +$430K
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$3.45M 2.95%
+135,169
New +$2.12M
CRBP icon
8
Corbus Pharmaceuticals
CRBP
$168M
$3.45M 2.95%
+87,846
New +$2.17M
DXCM icon
9
DexCom
DXCM
$27.1B
$3.44M 2.95%
24,828
– –
CNTA
10
DELISTED
Centessa Pharmaceuticals
CNTA
$3.11M 2.66%
+274,900
New +$2.6M
CLDX icon
11
Celldex Therapeutics
CLDX
$2.75B
$2.98M 2.56%
71,100
-40,200
-36% -$1.65M
GERN icon
12
Geron
GERN
$917M
$2.93M 2.51%
886,800
+279,300
+46% +$626K
JBIO
13
Jade Biosciences
JBIO
$1.18B
$2.91M 2.49%
+2,814
New +$2.15M
MOR
14
DELISTED
MorphoSys AG American Depositary Shares
MOR
$2.81M 2.4%
+154,800
New +$2.29M
TVTX icon
15
Travere Therapeutics
TVTX
$5.32B
$2.79M 2.39%
362,487
+278,500
+332% +$2.35M
KRYS icon
16
Krystal Biotech
KRYS
$9.86B
$2.62M 2.24%
+14,700
New +$2.04M
ISRG icon
17
Intuitive Surgical
ISRG
$120B
$2.54M 2.17%
6,358
– –
TARS icon
18
Tarsus Pharmaceuticals
TARS
$2.52B
$2.41M 2.06%
66,300
-18,100
-21% -$532K
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.6B
$2.11M 1.81%
7,900
-5,302
-40% -$1.25M
INZY
20
DELISTED
Inozyme Pharma
INZY
$2.09M 1.79%
+273,413
New +$1.5M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$6.98B
$1.98M 1.69%
45,603
-26,600
-37% -$1.16M
INSM icon
22
Insmed
INSM
$23.3B
$1.95M 1.67%
71,700
+10,200
+17% +$285K
ELEV
23
DELISTED
Elevation Oncology
ELEV
$1.89M 1.62%
+369,322
New +$1.2M
EXAS
24
DELISTED
Exact Sciences
EXAS
$1.84M 1.58%
+26,700
New +$1.69M
CYTK icon
25
Cytokinetics
CYTK
$11.1B
$1.82M 1.56%
26,008
-8,900
-25% -$688K
1
2 3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
MUAMU
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $193M AUM 37.43% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $194M AUM 20.19% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
CWRP
Cassady Wealth & Retirement Planning Henderson, Nevada $193M AUM

Exome Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Exome Asset Management held 80 positions worth $117M, up 15% from $101M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Exome Asset Management's Q1 2024 filing shows 28 new, 7 increased, 10 reduced and 27 closed positions. Its largest new stake was Centessa Pharmaceuticals: 274,900 shares worth $3.11M. The largest sale was Immunogen Inc, an estimated $5.54M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Exome Asset Management's largest Q1 2024 buy was Centessa Pharmaceuticals: 274,900 shares worth $3.11M.
  • Exome Asset Management added most to BeOne Medicines Ltd in Q1 2024, an estimated $3.86M increase.
  • Exome Asset Management's biggest Q1 2024 reduction was Alpine Immune Sciences Inc, cutting an estimated $1.67M.
  • Exome Asset Management fully exited Immunogen Inc in Q1 2024, selling an estimated $5.54M.
  • Exome Asset Management's ten largest holdings make up 40% of its $117M portfolio in Q1 2024.
  • Exome Asset Management opened 28 new positions and closed 27 in Q1 2024.
  • Exome Asset Management's portfolio value rose 15% quarter-over-quarter to $117M.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.